Kobayashi, Yoshihisa

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

Kobayashi, Y., & Mitsudomi, T. (2016) · Cancer Science

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 413

EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs

Kobayashi, Y., Togashi, Y., Yatabe, Y., Mizuuchi, H., Jangchul, P., Kondo, C., Shimoji, M., Sato, K., Suda, K., Tomizawa, K., et al. (2015) · Clinical Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 203

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?

Banno, E., Togashi, Y., Nakamura, Y., Chiba, M., Kobayashi, Y., Hayashi, H., Terashima, M., de Velasco, M. A., Sakai, K., Fujita, Y., et al. (2016) · Cancer Science

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 87

EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib

Kobayashi, Y., Fujino, T., Nishino, M., Koga, T., Chiba, M., Sesumi, Y., Ohara, S., Shimoji, M., Tomizawa, K., Takemoto, T., et al. (2018) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 65

Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers

Kobayashi, Y., Chhoeu, C., Li, J., Price, K. S., Kiedrowski, L. A., Hutchins, J. L., Hardin, A. I., Wei, Z., Hong, F., Bahcall, M., et al. (2022) · Nature

Protein Kinase Regulation and GTPase SignalingRNA Research and Splicing

Cited by 56